Institute of Membrane Proteins, POSTECH, Pohang, Republic of South Korea.
Department of Life Sciences, POSTECH, Pohang, Republic of South Korea.
Cancer Res Commun. 2023 Jan 18;3(1):80-96. doi: 10.1158/2767-9764.CRC-22-0246. eCollection 2023 Jan.
Tumor-associated macrophages (TAM) are involved in tumor progression, metastasis, and immunosuppression. Because TAMs are highly plastic and could alter their phenotypes to proinflammatory M1 in response to environmental stimuli, reeducating TAMs has emerged as a promising approach to overcoming the challenges of solid cancer treatment. This study investigated the effect of IL9 on macrophage M1 polarization and verified its antitumor potential to retrain TAMs and promote chemokine secretion. We demonstrated that IL9 stimulated macrophage proliferation and polarized them toward the proinflammatory M1 phenotype in an IFNγ-dependent manner. Tumor-localized IL9 also polarized TAMs toward M1 and made them release CCL3/4 and CXCL9/10 to recruit antitumor immune cells, including T and natural killer cells, into the tumor microenvironment. Furthermore, peritoneal treatment with recombinant IL9 delayed the growth of macrophage-enriched B16F10 melanoma and 4T1 breast cancer in syngeneic mice, although IL9 treatment did not reduce tumor growth in the absence of macrophage enrichment. These results demonstrate the efficacy of IL9 in macrophage polarization to trigger antitumor immunity.
These findings clarified the effect of IL9 on macrophage M1 polarization and verified its antitumor potential through retraining TAMs and chemokine secretion.
肿瘤相关巨噬细胞(TAM)参与肿瘤的进展、转移和免疫抑制。由于 TAM 具有高度可塑性,并能根据环境刺激改变其表型为促炎型 M1,因此重新教育 TAM 已成为克服实体瘤治疗挑战的一种有前途的方法。本研究探讨了 IL9 对巨噬细胞 M1 极化的影响,并验证了其通过重新训练 TAM 和促进趋化因子分泌来抑制肿瘤的潜力。我们证明,IL9 以 IFNγ依赖性方式刺激巨噬细胞增殖,并将其极化为促炎型 M1 表型。肿瘤局部的 IL9 也使 TAM 向 M1 极化,并使它们释放 CCL3/4 和 CXCL9/10,将抗肿瘤免疫细胞,包括 T 细胞和自然杀伤细胞,募集到肿瘤微环境中。此外,腹腔内给予重组 IL9 可延迟富含巨噬细胞的 B16F10 黑色素瘤和 4T1 乳腺癌在同基因小鼠中的生长,尽管在没有巨噬细胞富集的情况下,IL9 治疗并未减少肿瘤生长。这些结果表明 IL9 在巨噬细胞极化以触发抗肿瘤免疫方面的有效性。
这些发现阐明了 IL9 对巨噬细胞 M1 极化的影响,并通过重新训练 TAM 和趋化因子分泌验证了其抗肿瘤潜力。